This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by Gruppo Italiano MEsotelioma.
Recruitment status was:  Not yet recruiting
Information provided by:
Gruppo Italiano MEsotelioma Identifier:
First received: October 29, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
The purpose of this study is to evaluate the antitumor activity of a combination of Imatinib mesylate and Gemcitabine in patients with unresectable malignant mesothelioma expressing either PDGFR-beta or C-kit

Condition Intervention Phase
Mesothelioma Drug: Imatinib mesylate plus Gemcitabine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit

Resource links provided by NLM:

Further study details as provided by Gruppo Italiano MEsotelioma:

Primary Outcome Measures:
  • Overall response rate [ Time Frame: Every two months ]

Secondary Outcome Measures:
  • Progression-free-survival; Overall Survival; Safety [ Time Frame: Follow-up after end of treatment will be every three months; safety will be analyzed throughout the whole study ]

Estimated Enrollment: 56
Study Start Date: January 2008
Estimated Study Completion Date: December 2009
Arms Assigned Interventions
Experimental: I Drug: Imatinib mesylate plus Gemcitabine
Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles

  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age of > 18 years and < 72 years
  • Patients with a histologically proven malignant mesothelioma of the pleura or of the peritoneum, expressing either PDFGR-beta or C-Kit by immunochemistry (ICH)
  • Locally advanced disease, unsuitable for curative surgical resection, or metastatic disease
  • Confirmed progression of the disease according to modified REcist-criteria, documented after a first-line, systemic (premetrex+cisplatin regimen) or local treatment (i.e., intrapleuric)
  • ECOG Performance Status of 0, 1 or 2
  • Life expectancy of at least 3 months
  • Capability of understanding the objectives of the study and giving written informed consent
  • Willingness and ability to comply with study requirements
  • Sufficient caloric and fluid intake, including patients under enteral or parenteral nutrition

Exclusion Criteria:

  • Co-existing tumors of different histologic origin, except non melanomatous localized skin cancer and/or in situ cervical carcinoma
  • A history of earlier tumors of different histologic origin being in complete remission since less than 5 years
  • Unresolved toxicity from prior antitumor treatment(s)
  • Primary peritoneal mesothelioma
  • Any of the following abnormal baseline hematological values:

    • Hb < 9 g/dL
    • WBC < 3 x 109/L
    • Neutrophils < 1.5 x 109/L
    • Platelets < 100 x 109/L
    • Serum bilirubin > 2.5 mg/dL
    • ALAT and ASAT > 3 x UNL (unless due to liver metastases)
    • Serum creatinine > 1.5 mg/dL
  • Clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring medication, uncontrolled hypertension, overt cardiac failure or non compensated chronic heart disease in NYHA class II or more
  • History of psychiatric disabilities, potentially interfering with the capability of giving adequate informed consent
  • Pregnant or lactating women or inability/unwillingness to practice a medically approved method of contraception during study period (including 3 months following the end of treatment)
  • Uncontrolled active infections
  • Any condition which, in the judgement of the Investigator, would place the patient at undue risk or interfere with the results of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00551252

Contact: Camillo Porta, MD +39-0382-501355

Medical Oncology, IRCCS San Matteo University Hospital Foundation Not yet recruiting
Pavia, Italy, 27100
Principal Investigator: Camillo Porta, MD         
Sponsors and Collaborators
Gruppo Italiano MEsotelioma
Principal Investigator: Camillo Porta, MD Medical Oncology, IRCCS San Matteo University Hospital Foundation, pavia, Italy
  More Information

Additional Information:
Publications: Identifier: NCT00551252     History of Changes
Other Study ID Numbers: GIMe/01/06
Study First Received: October 29, 2007
Last Updated: October 29, 2007

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Imatinib Mesylate
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors processed this record on August 18, 2017